B

Blackrock Neurotech

Develops implantable neural interfaces for communication

Overview

Blackrock Neurotech develops brain-computer interface (BCI) technology. Its main offering is the Utah Array, a microelectrode device implanted in the brain to record neural signals, along with software and hardware to decode those signals so users can control computers, prosthetic limbs, or other devices. The company sells its BCI systems to research institutions and medical device companies and also provides engineering and consulting services to support implementation. Unlike many competitors that focus on noninvasive or software-only solutions, Blackrock Neurotech provides invasive neural interfaces with a complete hardware–software pipeline for recording, decoding, and using brain activity. Its goal is to help people with paralysis and other neurological disorders communicate and interact with their surroundings by restoring neural communication through implanted interfaces.

Significant Headcount Growth

Work here?Claim your company

About Blackrock Neurotech

Simplify's Rating
Why Blackrock Neurotech is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

51-200

Company Stage

Growth Equity (Venture Capital)

Total Funding

$24.1M

Headquarters

Salt Lake City, Utah

Founded

2008

Get referred to Blackrock Neurotech

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 MoveAgain expanded to a third clinical site, accelerating patient enrollment.
  • July 2026 safety and efficacy results strengthen reimbursement, regulatory, and partner confidence.
  • MindX integration and Tether's $200 million capital support a full-stack BCI rollout.

What critics are saying

  • Tether's 2024 majority stake ties Blackrock's strategy to one volatile crypto owner.
  • Blackrock still sells research-grade implants, leaving Neuralink and Precision Neuroscience to chase commercial clinics.
  • Any 2026 trial failure in MoveAgain or INTENT would delay commercialization for years.

What makes Blackrock Neurotech unique

  • Blackrock Neurotech's Utah Array has been used in humans since 2004.
  • June 2026 FDA breakthrough designation accelerated Blackrock's high-density recording array review.
  • July 2026 human ICMS data showed 27 implant-years without serious adverse events.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$24.1M

Above

Industry Average

Funded Over

4 Rounds

Growth Equity VC funding comparison data is currently unavailable. We're working to provide this information soon!
Growth Equity VC Funding Comparison Coming Soon

Benefits

  • Commuter Benefits
  • Paid Holidays
  • Paid Sick Leave
  • Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

13%

1 year growth

13%

2 year growth

9%
Cision
Jan 16th, 2025
Most Advanced Artificial Touch For Brain-Controlled Bionic Hand

Most advanced artificial touch for brain-controlled bionic hand

PR Newswire
Aug 9th, 2024
Wvu Medicine To Host Brain-Machine Interface (Bmi) Summit Charting The Future Of Neurotechnology

Leading Neuroscientists, Technologists, Regulators, and Venture Capitalists Convening in West VirginiaMORGANTOWN, W.Va., Aug. 9, 2024 /PRNewswire/ -- West Virginia University (WVU) Medicine will host an international gathering of scientists, engineers, researchers, physicians, and industry leaders at the Brain-Machine Interface (BMI) Summit this coming weekend. Organized by Dr. Peter Konrad of WVU Medicine and Dr. Jose "Pepe" Contreras-Vidal of the University of Houston, the event is a key programming component of the National Science Foundation's (NSF) Industry-University Cooperative Research Centers (IUCRC).The conference aims to advance the accessibility and sustainability of BMI technologies for patients with neurological conditions by underscoring the need for increased collaboration across industry, government, and university systems.The BMI Summit will feature presentations and panel discussions with prominent figures from the FDA, NIH, NSF, and VA, alongside industry leaders from companies including Blackrock Neurotech, Precision Neuroscience, and Synchron. Three pioneering patients – Ian Burkhardt, Nathan Copeland, and Jen French – who have been at the forefront of BMI device trials, demonstrating the transformative potential of these technologies will be sharing their crucial patient perspective for those dealing with disabling conditions like paralysis, stroke, speech loss, vision loss, pain, and brain injury."For 20 years, we've seen incredible advancements in BMI technology, but the journey from laboratory to bedside has too often been slow and fragmented," said Dr

Intelligence360 News
May 21st, 2024
Blackrock Neurotech Raises $12.4M in Funding

Blackrock Microsystems, operating as Blackrock Neurotech, has filed a notice with the U.S. SEC to raise $12.4 million in new equity investment. CEO Marcus Gerhardt played a key role in securing the funding, which will support the company's expansion and product development. Blackrock Neurotech specializes in neural implants and brain-computer interface technology aimed at restoring function and independence to individuals with neurological disorders.

Swipeline
Apr 30th, 2024
Tether Invests $200M in Blackrock Neurotech

Tether, a cryptocurrency company, has invested $200 million in US-based Blackrock Neurotech, a competitor to Elon Musk's Neuralink. Blackrock Neurotech develops brain chips aimed at helping individuals with neurological diseases regain abilities such as walking, talking, hearing, seeing, and feeling. The technology also enables users to control prosthetic limbs through thought and experience sensory feedback, enhancing interaction with robotic arms. The investment will help commercialize and launch the technology, already used by 40 people.

PYMNTS
Apr 29th, 2024
Tether Buys Majority of Blackrock Neurotech for $200M

Tether has invested $200 million to acquire a majority stake in Blackrock Neurotech, a leader in brain-computer-interface technology. This partnership aims to accelerate the development and commercialization of BCI technologies, which allow direct brain communication with devices, enhancing functions like operating robotic arms and driving cars. This move aligns with Tether's strategy to diversify its portfolio and invest in transformative technologies.

Recently Posted Jobs

Sign up to get curated job recommendations

Blackrock Neurotech is Hiring for 7 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs